On Thursday, an Arkansas jury favored Wyeth and determined the company had provided adequate warnings about associated risks with its hormone replacement therapy drugs. The medicine was neither defective nor the cause of a woman's breast cancer. After a day and a half of deliberations, Wyeth received a full victory when the jury also found they were not negligent in its promotion of the drugs...